Locally Advanced Nasopharyngeal CarcinomaPhase 3NCT07177443
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
A Phase 3 study testing Radiotherapy, Serplulimab and Cisplatin in people with Locally Advanced Nasopharyngeal Carcinoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Locally Advanced Nasopharyngeal Carcinoma
- What is being tested?
- Radiotherapy, Serplulimab and Cisplatin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 710 participants
- Where
- 1 siteChina
- Study dates
- 26 Sep 2025to 31 Dec 2035
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age at diagnosis: 18-65 years;
- Pathologically confirmed treatment-naïve nasopharyngeal carcinoma of "non-keratinizing type (WHO classification)";
- Locoregionally advanced nasopharyngeal carcinoma staged per the 9th edition of the American Joint Committee on Cancer (AJCC) staging system: Stage II (T1-3N2), Stage III(T1-4N3 or T4N1-2);
- ECOG performance status: 0-1;
- Post-induction therapy requirements:
- Radiological assessment showing ≥50% tumor regression (RECIST 1.1) Undetectable plasma EBV DNA levels;
Show all 16Show fewer
- Adequate bone marrow function:
- White blood cell count >4×10⁹/L Hemoglobin >90 g/L Platelet count >100×10⁹/L;
- Normal hepatic/renal function:
- Total bilirubin ≤1.5×upper limit of normal (ULN) AST/ALT ≤2.5×ULN Alkaline phosphatase ≤2.5×ULN Creatinine clearance ≥60 mL/min;
- Normal results for:
- Thyroid function tests Amylase and lipase Pituitary function Inflammatory/infection markers Cardiac enzymes Electrocardiogram
- Additional requirements:
- Pulmonary function tests for smokers >50 years Cardiac ultrasound + myocardial function tests for patients with ECG abnormalities or cardiovascular history (unless meeting exclusion criterion (8));
- Signed informed consent with willingness/compliance to follow study schedules for treatment, follow-up, and laboratory tests;
- For women of childbearing potential: Agreement to use reliable contraception (e.g., condoms, prescribed oral contraceptives) from screening until 1 year post-treatment.
Who cannot join
- Hepatitis B Virus (HBV) Infection:
- HBsAg-positive with HBV DNA >1×10³ copies/mL (patients with controlled viremia [<1×10³ copies/mL] after antiviral therapy are eligible).
- Hepatitis C Virus (HCV) Infection: Anti-HCV antibody-positive.
- HIV/AIDS: Anti-HIV antibody-positive or diagnosed with acquired immunodeficiency syndrome (AIDS).
- Active Tuberculosis (TB): History of active TB within the past year (regardless of treatment status). Exception: Patients with adequately treated past TB (confirmed by standard anti-TB therapy) may be enrolled if >1 year since completion of treatment.
- Active Autoimmune Diseases:Known or suspected autoimmune disorders (e.g., uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, hypothyroidism, or asthma requiring bronchodilators).
Show all 25Show fewer
- Exceptions:
- Type 1 diabetes mellitus Hypothyroidism managed with hormone replacement Skin conditions not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia).
- Interstitial Lung Disease (ILD):
- History of ILD or pneumonitis requiring oral/IV steroids within the past year.
- Immunosuppressive Therapy:
- Chronic systemic corticosteroids (≥10 mg prednisone equivalent/day) or other immunosuppressants within 4 weeks prior to enrollment. Inhaled/topical steroids are permitted.
- Uncontrolled Cardiac Disease: Heart failure (NYHA class ≥2), Unstable angina, Myocardial infarction within the past year, Clinically significant arrhythmias requiring treatment.
- Pregnancy/Lactation: Pregnant or breastfeeding women (urine/blood pregnancy test required for women of childbearing potential).
- Concurrent Malignancies:
- History of other malignancies except:
- Adequately treated non-melanoma skin cancer, Carcinoma in situ of the cervix, Papillary thyroid carcinoma.
- Hypersensitivity: Known allergy to any component of the study drugs or excipients.
- Active Infections:
- Systemic infections requiring treatment within 1 week prior to enrollment.
- Live Vaccines:
- Administration of live vaccines within 30 days before the first immunotherapy dose.
- Organ Transplantation: History of allogeneic organ transplantation.
- Other High-Risk Conditions:
- Any condition that may compromise patient safety or compliance per investigator assessment (e.g., severe psychiatric disorders, life-threatening comorbidities, or social/familial risk factors).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Wuhan Union Hospital
Wuhan, Hubei, 430022
Kunyu Mr. Yang, MD, +86 13995595360, wanc@hust.edu.cn
About this study
Official title: Induction Chemotherapy Combined With Serplulimab Induction/Maintenance Therapy and Omission of Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma (UNION-NPC-001): A Multicenter, Open-Label, Randomized, Controlled, Phase III, Non-Inferiority Clinical Trial
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).
Read the detailed description
This multicenter phase III trial enrolls high-risk locally advanced nasopharyngeal carcinoma patients (AJCC 9th edition, Stage T1-3N2 [II] or T1-4N3/T4N1-2 [III]) who achieves ≥50% tumor regression (RECIST v1.1) and undetectable plasma EBV DNA after three cycles of GP induction chemotherapy (gemcitabine + cisplatin) combined with serplulimab. Eligible patients will be randomized to either:
Experimental arm: Radiotherapy alone followed by serplulimab maintenance, or Control arm: Cisplatin-based concurrent chemoradiotherapy (CCRT) followed by serplulimab maintenance.
Primary study endpoint
- event-free survival (EFS) ② overall survival (OS) ③ Incidence of Hearing Loss (any grade) Secondary study endpoints
- 3-year distant metastasis-free survival (DMFS)
- 3-year locoregional recurrence-free survival (LRFS)
- Quality of life (QoL) assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 v3.0) and its head-and-neck cancer module (EORTC QLQ-H\&N35 v1.0), both validated Chinese versions.
- Incidence rate of investigator-reported adverse events (AEs)
- Incidence rate of patient-reported AEs
- Being tested
- Radiotherapy, Serplulimab, Cisplatin
- Keywords
- Cisplatin-based concurrent chemoradiotherapy, radiotherapy, Treatment De-escalation, locally advanced nasopharyngeal carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RadiotherapyRadiation
Following induction therapy, eligible patients will receive radiotherapy alone or concurrent chemoradiotherapy per protocol. Photon or proton radiotherapy techniques were permitted. Prescribed doses were:
Primary tumor and metastatic lymph nodes: 70 Gy/33 fractions High-risk lymphatic drainage areas: 60 Gy/33 fractions Low-risk regions: 54 Gy/33 fractions
PTV dose specifications:
GTVnx: 70 Gy GTVnd: 66-70 Gy (reducible to 63 Gy for suspicious small nodes) CTV1: 60-62 Gy CTV2: 54-56 Gy All treatments will employ simultaneous integrated boost (SIB) intensity-modulated radiotherapy delivered once daily, 5 fractions per week.
SerplulimabDrug
Serplulimab will be used in the induction phase for 3 cycles and the maintenance phase for 14 cycles.
CisplatinDrug
On days 64 and 85, patients will receive cisplatin chemotherapy at a dose of 100 mg/m² via intravenous infusion.
| Study group | Role | What they receive |
|---|---|---|
| Experimental arm | Experimental | Radiotherapy Receives: Radiation: Radiotherapy; Drug: Serplulimab |
| Control arm | Active comparator | Cisplatin-based concurrent chemoradiotherapy (CCRT) Receives: Radiation: Radiotherapy; Drug: Serplulimab; Drug: Cisplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Event-free survival (EFS)
EFS is defined as the time from the date of randomization to the first occurrence of disease recurrence (locoregional or distant) or death from any cause, whichever comes first.
Measured: 3-year
Overall survival (OS)
OS is defined as the time from the date of randomization until death from any cause.
Measured: 5-year
Incidence of Hearing Loss (any grade)
Proportion of participants experiencing any grade of hearing loss, assessed by pure-tone audiometry, auditory brainstem response, and acoustic immittance.
Measured: 3 years after radiotherapy
Secondary outcomes (6)
Distant metastasis-free survival (DMFS)
Time from randomization to the first occurrence of distant metastasis or death from any cause.
Measured: 3-year
Locoregional recurrence-free survival (LRFS)
LRFS is defined as the time from the date of randomization to the first histologically or radiologically confirmed locoregional recurrence or death from any cause.
Measured: 3-year
Health-Related Quality of Life assessed by EORTC QLQ-C30
Changes in health-related quality of life from baseline (informed consent) until 60 months after radiotherapy completion, assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), version 3.0. The QLQ-C30 includes functional scales (e.g., physical, role, emotional), global quality of life scale, and symptom scales (e.g., fatigue, pain, nausea/vomiting). Scores range from 0 to 100. For functional scales and global quality of life, a higher score represents a better level of functioning or well-being. For symptom scales, a higher score represents a greater severity of symptoms.
Measured: From baseline (at informed consent) up to 60 months after radiotherapy completion.
Head and Neck Cancer-Specific Symptoms assessed by EORTC QLQ-H&N35
Changes in head and neck cancer-specific symptoms and side effects from baseline (informed consent) until 60 months after radiotherapy completion, assessed using the EORTC Head and Neck Cancer Module (QLQ-H\&N35), version 1.0. The QLQ-H\&N35 assesses symptoms relevant to head and neck cancer patients (e.g., pain, swallowing, senses, speech, social eating). Scores range from 0 to 100. For all symptom scales, a higher score represents a greater severity of symptoms.
Measured: From baseline (informed consent) until 60 months after radiotherapy completion.
Incidence rate of investigator-reported adverse events (AEs)
Analysis of investigator-reported adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0.
Measured: 3-year
Incidence rate of patient-reported adverse events (AEs)
Analysis of patient-reported adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by patients themselves
Measured: 3-year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start26 Sep 2025
- Primary completion31 Dec 2035 (estimated)
- Study completion31 Dec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Locally Advanced Nasopharyngeal CarcinomaStudies of the same condition, open and under way.
- More trials run by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 710 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07177443
- Sponsor's protocol ID
- UNION-NPC-001
- Status last verified
- Sep 2026
- First submitted
- 5 Aug 2025
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Induction Chemotherapy Combined With Serplulimab Induction/Maintenance Therapy and Omission of Concurrent Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma (UNION-NPC-001): A Multicenter, Open-Label, Randomized, Controlled, Phase III, Non-Inferiority Clinical Trial
- ClinicalTrials.gov ID
- NCT07177443
- Acronym / sponsor ID
- UNION-NPC-001
- Keywords
- Cisplatin-based concurrent chemoradiotherapy, radiotherapy, Treatment De-escalation, locally advanced nasopharyngeal carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 710 participants (estimated)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 26 Sep 2025 (actual)
- Primary completion
- 31 Dec 2035 (estimated)
- Study completion
- 31 Dec 2035 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced nasopharyngeal carcinoma (LA-NPC).
Detailed description
This multicenter phase III trial enrolls high-risk locally advanced nasopharyngeal carcinoma patients (AJCC 9th edition, Stage T1-3N2 [II] or T1-4N3/T4N1-2 [III]) who achieves ≥50% tumor regression (RECIST v1.1) and undetectable plasma EBV DNA after three cycles of GP induction chemotherapy (gemcitabine + cisplatin) combined with serplulimab. Eligible patients will be randomized to either:
Experimental arm: Radiotherapy alone followed by serplulimab maintenance, or Control arm: Cisplatin-based concurrent chemoradiotherapy (CCRT) followed by serplulimab maintenance.
Primary study endpoint
- event-free survival (EFS) ② overall survival (OS) ③ Incidence of Hearing Loss (any grade) Secondary study endpoints
- 3-year distant metastasis-free survival (DMFS)
- 3-year locoregional recurrence-free survival (LRFS)
- Quality of life (QoL) assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 v3.0) and its head-and-neck cancer module (EORTC QLQ-H\&N35 v1.0), both validated Chinese versions.
- Incidence rate of investigator-reported adverse events (AEs)
- Incidence rate of patient-reported AEs
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental arm | Experimental | Radiation: Radiotherapy, Drug: SerplulimabRadiotherapy |
| Control arm | Active comparator | Radiation: Radiotherapy, Drug: Serplulimab, Drug: CisplatinCisplatin-based concurrent chemoradiotherapy (CCRT) |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Age at diagnosis: 18-65 years;
- Pathologically confirmed treatment-naïve nasopharyngeal carcinoma of "non-keratinizing type (WHO classification)";
- Locoregionally advanced nasopharyngeal carcinoma staged per the 9th edition of the American Joint Committee on Cancer (AJCC) staging system: Stage II (T1-3N2), Stage III(T1-4N3 or T4N1-2);
- ECOG performance status: 0-1;
- Post-induction therapy requirements:
Key exclusion criteria (25 listed)
- Hepatitis B Virus (HBV) Infection:
- HBsAg-positive with HBV DNA >1×10³ copies/mL (patients with controlled viremia [<1×10³ copies/mL] after antiviral therapy are eligible).
- Hepatitis C Virus (HCV) Infection: Anti-HCV antibody-positive.
- HIV/AIDS: Anti-HIV antibody-positive or diagnosed with acquired immunodeficiency syndrome (AIDS).
- Active Tuberculosis (TB): History of active TB within the past year (regardless of treatment status). Exception: Patients with adequately treated past TB (confirmed by standard anti-TB therapy) may be enrolled if >1 year since completion of treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RadiotherapyFollowing induction therapy, eligible patients will receive radiotherapy alone or concurrent chemoradiotherapy per protocol. Photon or proton radiotherapy techniques were permitted. Prescribed doses were: Primary tumor and metastatic lymph nodes: 70 Gy/33 fractions High-risk lymphatic drainage areas: 60 Gy/33 fractions Low-risk regions: 54 Gy/33 fractions PTV dose specifications: GTVnx: 70 Gy GTVnd: 66-70 Gy (reducible to 63 Gy for suspicious small nodes) CTV1: 60-62 Gy CTV2: 54-56 Gy All treatments will employ simultaneous integrated boost (SIB) intensity-modulated radiotherapy delivered once daily, 5 fractions per week. | Radiation | Control arm, Experimental arm |
| SerplulimabSerplulimab will be used in the induction phase for 3 cycles and the maintenance phase for 14 cycles. | Drug | Control arm, Experimental arm |
| CisplatinOn days 64 and 85, patients will receive cisplatin chemotherapy at a dose of 100 mg/m² via intravenous infusion. | Drug | Control arm |
Primary outcome
Event-free survival (EFS)
Time frame: 3-year
EFS is defined as the time from the date of randomization to the first occurrence of disease recurrence (locoregional or distant) or death from any cause, whichever comes first.
Overall survival (OS)
Time frame: 5-year
OS is defined as the time from the date of randomization until death from any cause.
Incidence of Hearing Loss (any grade)
Time frame: 3 years after radiotherapy
Proportion of participants experiencing any grade of hearing loss, assessed by pure-tone audiometry, auditory brainstem response, and acoustic immittance.
6 secondary outcomes
Distant metastasis-free survival (DMFS)
Time frame: 3-year
Locoregional recurrence-free survival (LRFS)
Time frame: 3-year
Health-Related Quality of Life assessed by EORTC QLQ-C30
Time frame: From baseline (at informed consent) up to 60 months after radiotherapy completion.
Head and Neck Cancer-Specific Symptoms assessed by EORTC QLQ-H&N35
Time frame: From baseline (informed consent) until 60 months after radiotherapy completion.
Incidence rate of investigator-reported adverse events (AEs)
Time frame: 3-year
Incidence rate of patient-reported adverse events (AEs)
Time frame: 3-year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Locally Advanced Nasopharyngeal Carcinoma
RecruitingPhase 1/2
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
RecruitingPhase 2
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma (NPC)
RecruitingPhase 1/2
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Solid Tumor Cancer, Locally Advanced
Active, not recruitingPhase 2
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Not yet recruitingPhase 2
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma (NPC)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Radiotherapy, Serplulimab and Cisplatin in people with Locally Advanced Nasopharyngeal Carcinoma, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chao Wan (+86 18062775069, wanc@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Event-free survival (EFS) (time frame: 3-year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.